AnaptysBio (NASDAQ:ANAB) announced its earnings results on Thursday. The biotechnology company reported ($0.66) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.71) by $0.05, Fidelity Earnings reports. The business had revenue of $5.00 million during the quarter.
AnaptysBio stock opened at $72.33 on Friday. The stock has a market capitalization of $2.07 billion, a P/E ratio of -47.59 and a beta of 3.47. AnaptysBio has a 12-month low of $65.93 and a 12-month high of $134.00. The company has a current ratio of 16.19, a quick ratio of 16.19 and a debt-to-equity ratio of 0.01.
A number of analysts have recently weighed in on ANAB shares. Credit Suisse Group set a $147.00 target price on AnaptysBio and gave the company a “buy” rating in a research note on Thursday, September 27th. Cantor Fitzgerald set a $124.00 target price on AnaptysBio and gave the company a “buy” rating in a research note on Saturday, September 22nd. JMP Securities lowered their target price on AnaptysBio from $180.00 to $153.00 and set a “buy” rating for the company in a research note on Wednesday, August 15th. Stifel Nicolaus set a $127.00 target price on AnaptysBio and gave the company a “buy” rating in a research note on Friday, September 14th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $121.00 target price on shares of AnaptysBio in a research note on Tuesday, August 7th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $130.50.
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.
Read More: Discount Rate
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.